Utama › Kanser Pundi Kencing › North Carolina
Kajian klinikal Kanser Pundi Kencing di North Carolina
26 kajian untuk Kanser Pundi Kencing sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- dan 6 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06770582Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Margaret R Pardee Memorial Hospital, Hendersonville
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT03866382Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Duke Cancer Center Cary, Cary
- Duke University Medical Center (location of scans), Durham
- Duke University Medical Center - Duke University Hospital (location of scans), Durham
- dan 5 lagi
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07421700A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Biorepository and Precision Pathology Center (BRPC), Durham
- Duke Cancer Institute, Durham
- Substrate Services Core Research Support (SSCRS), Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07206225DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 130 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07124000A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- WakeMed Raleigh Campus ( Site 0811), Raleigh
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07419295A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Levine Cancer Institute, Charlotte
- Oncology Specialists of Charlotte, Charlotte
- Wake Forest Baptist Health, Winston-Salem
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07218380Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05267626A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Duke University Medical Center - Duke Cancer Center, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07217171ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- University of North Carolina, Chapel Hill
- Atrium Health/Levine Center, Charlotte
- Associated Urologist of North Carolina (Solaris), Raleigh
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06567743The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 45 hingga 75 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06995898FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT05614739Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Chapel Hill
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07129993Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT07097142LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- UNC Chapel Hill Hospital, Chapel Hill
- Duke Health - Duke Cancer Center, Durham
- Associated Urologists of North Carolina, Raleigh
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- University of North Carolina, Chapel Hill
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07225127A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
Mengambil pesertaFasa 2
Umur 8 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05503797A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
- UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill
- Carolinas Medical Center (biopsy only), Charlotte
- dan 10 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT04879329PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT06896162Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy
- Duke University, Durham
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mei 2026 · NCT06986304Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Feb 2026 · NCT07030257A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Feb 2026 · NCT06778863SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.